Clonal hematopoiesis of indeterminate potential (CHIP) is an age-related condition where a mutation in hematopoietic stem cells gives them a growth advantage. This can lead to various age-related diseases, with recent research suggesting a link between CHIP and accelerated progression of chronic kidney disease. Studies have shown that CHIP may worsen inflammation and kidney function decline in CKD patients, highlighting the need for further research in this area.
In a recent study, researchers investigated the impact of CHIP on chronic kidney disease progression in over 6,000 individuals across four large CKD cohorts. Using Mendelian randomization and mouse models, they found that non-DNMT3A CHIP was associated with a higher risk of kidney function decline and inflammation in CKD patients. These findings suggest that CHIP may play a significant role in worsening CKD outcomes and could be a potential target for future treatments.
